Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies

July 13, 2018 by Website Admin in

Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets

Tweet

Share

Pin it

Previous StoryMoleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market Next StoryMoleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover